| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | NEUTRAL | NEUTRAL | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.22▼ | 1.15▲ | 1.09▲ | 1.17▲ | 1.03▲ |
| MA10 | 1.14▲ | 1.00▲ | 0.97▲ | 1.04▲ | 1.21▼ |
| MA20 | 1.04▲ | 1.08▲ | 1.10▲ | 1.00▲ | 1.35▼ |
| MA50 | 1.32▼ | 1.38▼ | 1.39▼ | 1.24▼ | 1.83▼ |
| MA100 | 1.45▼ | 1.46▼ | 1.50▼ | 1.36▼ | 1.94▼ |
| MA200 | 1.66▼ | 1.80▼ | 1.82▼ | 1.69▼ | 8.52▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.044▲ | 0.046▲ | 0.043▲ | 0.058▲ | -0.018▼ |
| RSI | 49.734▼ | 49.660▼ | 49.685▼ | 55.912▲ | 41.338▼ |
| STOCH | 70.002 | 52.421 | 44.400 | 70.447 | 17.308▼ |
| WILL %R | -41.107 | -41.107 | -41.107 | -42.105 | -57.584 |
| CCI | 33.176 | 64.491 | 57.725 | 119.461▲ | -18.842 |
|
Monday, March 30, 2020 05:00 AM
Crucial life-saving initiative led by Dr. Steven Quay for clinical trials on the safety and efficacy of a combination of FDA-approved drugs (nebulized Heparin-N-acetylcysteine ...
|
|
Saturday, March 28, 2020 04:27 AM
Atossa Genetics (NASDAQ:ATOS) released its quarterly earnings data on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) ...
|
|
Thursday, March 26, 2020 05:00 AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/04/20 | 1.39 | 1.39 | 1.19 | 1.20 | 107,000 |
| 31/03/20 | 1.24 | 1.37 | 1.20 | 1.33 | 262,300 |
| 30/03/20 | 1.13 | 1.50 | 1.13 | 1.18 | 819,490 |
| 27/03/20 | 1.10 | 1.13 | 1.00 | 1.04 | 51,000 |
| 26/03/20 | 1.02 | 1.15 | 1.02 | 1.10 | 132,100 |
| 25/03/20 | 0.94 | 1.09 | 0.93 | 1.03 | 100,200 |
| 24/03/20 | 0.92 | 0.94 | 0.90 | 0.94 | 111,700 |
| 23/03/20 | 0.93 | 0.93 | 0.8301 | 0.9089 | 54,141 |
| 20/03/20 | 0.82 | 0.95 | 0.82 | 0.88 | 128,800 |
| 19/03/20 | 0.86 | 0.86 | 0.79 | 0.83 | 68,200 |
|
|
||||
|
|
||||
|
|